Immunovia AB: Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

LUND, Sweden–(BUSINESS WIRE)–Immunovia AB announced today that the company is expanding the applications area of IMMray™, its proprietary antibody biomarker based technology platform, to autoimmune diseases. “It is estimated that 5 million people suffer from SLE worldwide, with 100,000 new cases reported every year. Due to the challenge of diagnosing SLE patients correctly, there is an immediate clinical need for a blood-based test such as IMMray™ SLE”, said Mats Grahn, CEO, Immunovia. A new
Source: BusinessWire-Primary

Immunovia AB: Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures